Published in Vaccine Weekly, April 28th, 2004
Innogenetics will develop and commercialize current product candidates in Genencor's vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor. Genencor will recognize license fees in the first year totaling $10 million, and will receive further payments of up to $87 million as development milestones are achieved.
Genencor will also receive royalty payments on product sales. Genencor plans to apply the funds from this transaction...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.